Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma

Inclusion Criteria: 1. Age 18\~75 years old, both male and female; 2. Stage 1: pathologically diagnosed, incurable advanced HCC subjects who have failed standard treatment or were unwilling to accept standard treatment; 3. Stage 2: pathologically diagnosed, incurable advanced HCC subjects, who have no prior immunotherapy, no more than 1 line of previous system treatment; 4. At least one measurable lesion based on RECIST v1.1 criteria; 5. Barcelona clinic liver cancer: Stage B or C; 6. ECOG PS score: 0-1 points; 7. Child-Pugh score: ≤ 7; 8. Expected survival period ≥ 3 months; 9. Adequate organ function. Exclusion Criteria: 1. Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma / hepatocellular carcinoma; 2. Patients with any active, known or suspected autoimmune disorder; 3. Systemic treatment with corticosteroids or other immunosuppressants within 1 month before the first dose; 4. With known severe allergic reactions to any other monoclonal antibodies; 5. Patients with known CNS metastasis or hepatic encephalopathy; 6. Patients with liver tumor burden greater than 50% of total liver in volume, or patients who have previously undergone liver transplantation; 7. Patients with symptomatic ascites or pleural effusion requiring paracentesis and drainage, or patients who have undergone ascites or pleural effusion drainage within 2 weeks before the first dose; 8. Patients with other malignancies currently or within the past 5 years; 9. Patients with hypertension which cannot be well controlled by antihypertensives; 10. Uncontrolled cardiac diseases or symptoms; 11. Patients with other potential factors that may affect the study results.